Register medical devices to place on the market

Recommendations from the independent Expert Advisory Group to the MHRA on the use of paclitaxel balloon catheters and stents to treat peripheral arterial disease.

There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, with different stated mg dose but similar bioavailability, will both be available on the market.

Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.

As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.

List of Field Safety Notices from 11 to 15 August 2025.

Patients implanted with affected devices should expect to be contacted directly for a follow-up assessment, if required.